两种不同方法制备普通冰冻血浆的质量对比研究

Qualitative Comparison between Two Different Preparation Methods of Ordinarily Frozen Plasma

探讨两种方法制备普通冰冻血浆的质量差异。采集100袋(200ml/袋)ACD-B保存的全血,随机均分为两个实验组。第一组在采血24h内离心分离血浆制备成普通冰冻血浆(Ⅰ型普浆),置于-30℃低温冰箱冰冻保存30d;第二组在采血6h内离心分离制备成新鲜冰冻血浆,置于-30℃低温冰箱冰冻保存7d,用4℃冷藏箱法制备冷沉淀,分离出的普通冰冻血浆(Ⅱ型普浆),置于-30℃保存23d。两组保存30d后,取出各组血浆于37℃水浴融化后检测凝血因子Ⅱ(FⅡ),凝血因子Ⅴ(FⅤ),凝血因子Ⅶ(FⅦ),凝血因子Ⅷ(FⅧ),凝血因子Ⅸ(FⅨ),凝血因子Ⅹ(FⅩ)活性(%)和纤维蛋白原(Fib)含量(g/L)。结果表明Ⅰ型普浆的FⅡ,FⅤ,FⅦ,FⅧ,FⅩ和Fib的活性水平明显高于Ⅱ型普浆(P<0.01);而FⅨ的活性水平无显著改变(P>0.05)。Ⅱ型普浆低于Ⅰ型普浆的质量,但其仍有较高的凝血因子水平,除非需大剂量补充凝血因子的特殊患者外,也可以部分代替新鲜冰冻血浆补充凝血因子。但其制备工艺有待改进和优化,以降低凝血因子的损失,提高其普通冰冻血浆的质量。

To explore the general difference in the quality of ordinary frozen plasma produced by two methods. 100 bags （200 mL/bag） of the ACD-B preseved whole blood, divided into two experimental groups in random. In the first group liquid plasma was separated from whole blood within 24 h of collection and placed at -30℃ for 30 days; In the second group fresh frozen plasma was separated from whole blood within 6 hs of collection and placed at - 30% for 7 days, which was thawed at 4℃ to get cryoprecipitate and lipid plasma and the latter was placed at - 30℃ for 23 days. At the end of 30 days, two groups of plasma were melt at 37℃ water bath and detected the activity of coagulation factor Ⅱ （ F Ⅱ ）, coagulation factor Ⅴ （ F Ⅴ ）, coagulation factor Ⅶ （ FⅦ）, coagulation factor Ⅷ （FⅧ）, coagulation factor Ⅸ （FⅨ）, coagulation factor Ⅹ （FⅩ） （%） and the concentration of fibrinogen （Fib） （g/L）. In the first group of ordinary frozen plasma, the activity of F Ⅱ, FⅤ, FⅦ, FⅧ, FX Fib were significantly higher than that of the second group （ P 〈 0. 01 ） ; and there was no significant difference in the activity of FⅨ between two groups （P 〉 0. 05 ）. The quality of ordinary frozen plasma produced as a byproduct of cyoprecipitate is poorer than that separated from whole blood within 24 h, but there is still a higher level of coagulation factors in the former, which can provide coagulation factors as a substitute for fresh frozen plasma except for some patients requiring a large dose of clotting factor. However, the technology of preparation need for improvement and optimization, in order to reduce the loss of coagulation factors to improve the quality of ordinary frozen plasma.